The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The closing price of UroGen Pharma Ltd (NASDAQ: URGN) was $19.4 for the day, down -1.57% from the previous closing price of $19.71. In other words, the price has decreased by -$1.57 from its previous closing price. On the day, 0.58 million shares were traded. URGN stock price reached its highest trading level at $20.09 during the session, while it also had its lowest trading level at $19.345.
Ratios:
Our analysis of URGN’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 3.99 and its Current Ratio is at 4.14.
On April 16, 2025, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $23.Scotiabank initiated its Sector Outperform rating on April 16, 2025, with a $23 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 11 ’25 when Schoenberg Mark sold 10,000 shares for $17.69 per share. The transaction valued at 176,900 led to the insider holds 148,229 shares of the business.
Smith Jason Drew sold 7,522 shares of URGN for $143,971 on Jul 28 ’25. The General Counsel now owns 41,492 shares after completing the transaction at $19.14 per share. On Jul 28 ’25, another insider, Schoenberg Mark, who serves as the Chief Medical Officer of the company, sold 5,149 shares for $19.14 each. As a result, the insider received 98,552 and left with 158,229 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, URGN now has a Market Capitalization of 897523520 and an Enterprise Value of 868039168. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.52. Its current Enterprise Value per Revenue stands at 9.211 whereas that against EBITDA is -7.105.
Stock Price History:
The Beta on a monthly basis for URGN is 1.12, which has changed by 0.2933333 over the last 52 weeks, in comparison to a change of 0.15222645 over the same period for the S&P500. Over the past 52 weeks, URGN has reached a high of $21.01, while it has fallen to a 52-week low of $3.42. The 50-Day Moving Average of the stock is 25.77%, while the 200-Day Moving Average is calculated to be 66.32%.
Shares Statistics:
URGN traded an average of 3.16M shares per day over the past three months and 1140110 shares per day over the past ten days. A total of 46.20M shares are outstanding, with a floating share count of 39.55M. Insiders hold about 14.51% of the company’s shares, while institutions hold 92.28% stake in the company. Shares short for URGN as of 1753920000 were 7165041 with a Short Ratio of 2.27, compared to 1751241600 on 5452730. Therefore, it implies a Short% of Shares Outstanding of 7165041 and a Short% of Float of 15.73.
Earnings Estimates
The stock of UroGen Pharma Ltd (URGN) is currently drawing attention from 7.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$0.39, with high estimates of $0.05 and low estimates of -$0.67.
Analysts are recommending an EPS of between -$2.4 and -$3.37 for the fiscal current year, implying an average EPS of -$2.99. EPS for the following year is -$1.63, with 6.0 analysts recommending between -$0.65 and -$2.71.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 8 analysts. It ranges from a high estimate of $42.1M to a low estimate of $28.64M. As of the current estimate, UroGen Pharma Ltd’s year-ago sales were $25.2MFor the next quarter, 8 analysts are estimating revenue of $44.56M. There is a high estimate of $53.34M for the next quarter, whereas the lowest estimate is $32.92M.
A total of 8 analysts have provided revenue estimates for URGN’s current fiscal year. The highest revenue estimate was $136M, while the lowest revenue estimate was $106.03M, resulting in an average revenue estimate of $123.68M. In the same quarter a year ago, actual revenue was $90.4MBased on 8 analysts’ estimates, the company’s revenue will be $261.67M in the next fiscal year. The high estimate is $391.48M and the low estimate is $224.5M.
